Yoko Obata1, Takahiro Takazono2,3, Masato Tashiro2,4, Yuki Ota5, Tomotaro Wakamura6, Akinori Takahashi7, Kumiko Sato7, Taiga Miyazaki2,3, Tomoya Nishino5, Koichi Izumikawa2,4. 1. Department of Nephrology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. yobata-ngs@umin.ac.jp. 2. Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. 3. Department of Respiratory Medicine, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. 4. Nagasaki University Infection Control and Education Center, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. 5. Department of Nephrology, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki, 852-8501, Japan. 6. Medical Affairs Division, Sumitomo Dainippon Pharma Co., Ltd, 1-13-1 Kyobashi, Chuo-ku, Tokyo, 104-8356, Japan. 7. Deloitte Tohmatsu Consulting LLC, Marunouchi Nijubashi Building, 3-2-3 Marunouchi, Chiyoda-ku, Tokyo, 100-8361, Japan.
Abstract
BACKGROUND: Liposomal amphotericin B (L-AMB), a broad-spectrum antifungicidal drug, is often used to treat fungal infections. However, clinical evidence of its use in patients with renal dysfunction, especially those receiving renal replacement therapy (RRT), is limited. Therefore, we evaluated the usage and occurrence of adverse reactions during L-AMB therapy in patients undergoing RRT. METHODS: Using claims data and laboratory data, we retrospectively evaluated patients who were administered L-AMB. The presence of comorbidities, mortality rate, treatment with L-AMB and other anti-infective agents, and the incidence of adverse reactions were compared between patients receiving RRT, including continuous renal replacement therapy (CRRT) and maintenance hemodialysis (HD), and those that did not receive RRT. RESULTS: In total, 900 cases met the eligibility criteria: 24, 19, and 842 cases in the maintenance HD, CRRT, and non-RRT groups, respectively. Of the patients administered L-AMB, mortality at discharge was higher for those undergoing either CRRT (15/19; 79%) or maintenance HD (16/24; 67%) than for those not receiving RRT (353/842; 42%). After propensity score matching, the average daily and cumulative dose, treatment duration, and dosing interval for L-AMB were not significantly different between patients receiving and not receiving RRT. L-AMB was used as the first-line antifungal agent for patients undergoing CRRT in most cases (12/19; 63%). Although the number of subjects was limited, the incidence of adverse events did not markedly differ among the groups. CONCLUSION: L-AMB may be used for patients undergoing maintenance HD or CRRT without any dosing, duration, or interval adjustments.
BACKGROUND: Liposomal amphotericin B (L-AMB), a broad-spectrum antifungicidal drug, is often used to treat fungal infections. However, clinical evidence of its use in patients with renal dysfunction, especially those receiving renal replacement therapy (RRT), is limited. Therefore, we evaluated the usage and occurrence of adverse reactions during L-AMB therapy in patients undergoing RRT. METHODS: Using claims data and laboratory data, we retrospectively evaluated patients who were administered L-AMB. The presence of comorbidities, mortality rate, treatment with L-AMB and other anti-infective agents, and the incidence of adverse reactions were compared between patients receiving RRT, including continuous renal replacement therapy (CRRT) and maintenance hemodialysis (HD), and those that did not receive RRT. RESULTS: In total, 900 cases met the eligibility criteria: 24, 19, and 842 cases in the maintenance HD, CRRT, and non-RRT groups, respectively. Of the patients administered L-AMB, mortality at discharge was higher for those undergoing either CRRT (15/19; 79%) or maintenance HD (16/24; 67%) than for those not receiving RRT (353/842; 42%). After propensity score matching, the average daily and cumulative dose, treatment duration, and dosing interval for L-AMB were not significantly different between patients receiving and not receiving RRT. L-AMB was used as the first-line antifungal agent for patients undergoing CRRT in most cases (12/19; 63%). Although the number of subjects was limited, the incidence of adverse events did not markedly differ among the groups. CONCLUSION:L-AMB may be used for patients undergoing maintenance HD or CRRT without any dosing, duration, or interval adjustments.
Authors: J Morgan; K A Wannemuehler; K A Marr; S Hadley; D P Kontoyiannis; T J Walsh; S K Fridkin; P G Pappas; D W Warnock Journal: Med Mycol Date: 2005-05 Impact factor: 4.076
Authors: Ihor Bekersky; Robert M Fielding; Dawna E Dressler; Jean W Lee; Donald N Buell; Thomas J Walsh Journal: Antimicrob Agents Chemother Date: 2002-03 Impact factor: 5.191
Authors: J W Lee; M A Amantea; P A Francis; E E Navarro; J Bacher; P A Pizzo; T J Walsh Journal: Antimicrob Agents Chemother Date: 1994-04 Impact factor: 5.191
Authors: Jane P Barrett; Katerina A Vardulaki; Christopher Conlon; Jonathan Cooke; Pascual Daza-Ramirez; E Glyn V Evans; Peter M Hawkey; Raoul Herbrecht; David I Marks; Jose M Moraleda; Gilbert R Park; Stephen J Senn; Claudio Viscoli Journal: Clin Ther Date: 2003-05 Impact factor: 3.393